Pacira BioSciences, Inc. (PCRX): Completion of Acquisition or Disposition of Assets

Pacira BioSciences, Inc. (PCRX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 November 17, 2026 To: Holders of Pacira BioSciences, Inc. 2.125% Convertible Senior Notes due 2029 (CUSIP: 695127AJ9) and Computershare Trust Company, National Association as Trustee, Paying Agent and Conversion Agent Corporate Trust Office 1505 Energy Park Drive St.

Event · M&A · completed
Role
target
Counterparty
Viatris Inc.
Price per share
$36.50
Consideration
cash

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 17, 2026, 2:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 2:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$PCRX
Bullish
high confidence
Mentioned
$PCRX
Relevance
9/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PCRXBullishMed
01

Why it matters

The filing confirms transaction completion and specifies that, after the effective time, holders convert the 2.125% notes into cash only, not PCRX shares, using $36.50 as the reference last reported sale price.

02

Market read

Confirms deal completion and clarifies convertible-note conversion mechanics, which can drive deal-arb and credit-sensitive positioning.

03

What to watch

Traders should monitor the make-whole adjustment and the exact conversion-rate increase timing for notes surrendered during the make-whole fundamental change window.

Relevance 9/10Novelty 8/10Timing: effective date of the merger is Nov. 17, 2026, with conversion window running into Jan. 8, 2027

Background

Pacira entered an Agreement and Plan of Merger with Viatris, with a tender offer launched Oct. 30, 2026 and consummated Nov. 17, 2026.

Company-level read

Ticker impact

$PCRXBullishHigh confidence
Context

Pacira’s 8-K says the Viatris tender offer closed Nov. 17, 2026, converting PCRX shares into the $36.50 cash merger consideration.

Expected impact

Likely support for PCRX around the $36.50 offer price as the market prices completion and noteholders adjust conversion expectations.

Evidence & confidence

The filing is a primary SEC disclosure of transaction consummation and the post-merger conversion right change for PCRX’s 2.125% notes.

Market effects

Limited direct sector read-through; this is primarily a capital-structure and deal-arbitrage catalyst for the issuer.

No clear regional spillover beyond US biotech M&A/deal-arb flows.

Low; transaction is US-listed and the disclosure is focused on note conversion mechanics.

Counterpoint

The conversion-right change may increase selling pressure from noteholders who prefer cash conversion, partially offsetting deal-arb support.

Key entities

  • Pacira BioSciences, Inc.

    Subject of the 8-K; merger close triggers common stock change event and supplemental indenture for convertible notes.

  • Viatris Inc.

    Parent in the merger agreement; commenced and consummated the tender offer to acquire all outstanding PCRX shares.

  • Peach Purchaser Sub Inc.

    Wholly owned subsidiary of Viatris that merged into Pacira as the surviving corporation.

  • Computershare Trust Company, National Association

    Trustee, paying agent, and conversion agent under the 2029 convertible notes indenture.

Related articles

$VTRSMedAI 8/10

Viatris Completes Acquisition of Pacira BioSciences

Viatris Inc. (VTRS) completed its acquisition of Pacira BioSciences (PCRX) for $36.50 per share. The deal, announced in October, aims to strengthen Viatris's U.S. pain management business. Pacira's shares will be delisted from Nasdaq, and Viatris expects the acquisition to add $90M-$100M in revenue for the rest of 2026.

$PCRXLow

Pacira BioSciences, Inc. (PCRX): RDF has the right to terminate the agreement for an uncured material breach by the Company, in connection with its bankruptcy or insolvency or if it directly…

Pacira BioSciences, Inc. (PCRX) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD Disclosure. As previously disclosed, pursuant to an agreement entered into between the Research Development Foundation (“RDF”) and a wholly-owned subsidiary of Pacira BioSciences, Inc. (the “Company” or “Pacira”), the Company was required to pay RDF a low